🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Impact of Surgical Procedures on Postoperative Outcomes in Cataract Phacoemulsification and Analysis of Related Factors

Recruitingn/aAges 50 Years - 90 YearsAllZhongshan Ophthalmic Center, Sun Yat-sen Universi…
NCT07550907 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to evaluate the location of phacoemulsification tip measured by intraoperative OCT during cataract surgeries and its impact on early postoperative changes of cornea and visual acuity. The main question it aims to answer is: In patients with age-related cataracts undergoing phacoemulsification, does the location (supracapsular, iris-lens diaphragm, or endocapsular) of the phaco tip affect postoperative corneal changes and visual acuity at early postoperative stage? Eyes having phacoemulsification for cataracts will receive intraoperative OCT imaging to evaluate the location of the phaco tip during surgery, and corneal changes and visual acuity will be measured postoperatively.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 50 years and ≤ 90 years * Diagnosis of unilateral/bilateral age-related cataract * Nuclear grade ≥2 in LOCSIII classification * Scheduled for cataract phacoemulsification combined with intraocular lens implantation * Pupil size ≥6mm after dilation * Corneal endothelial cell count ≥1500 cells/mm² Exclusion Criteria: * Diagnosis of severe systemic disease (e.g., severe hypertension or Alzheimer's disease) * History of ocular trauma or surgery * Presence of other ocular diseases (such as glaucoma, diabetic retinopathy, or high myopia) * Other ocular factors that may complicate the surgery (such as small pupil, shallow anterior chamber)
💊

What it tests

  • cataract surgery
📍

Where

1 site
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy